PDS Biotechnology Announces Strategic Refocus To Prioritize PDS0301 In Metastatic Colorectal Cancer; Expects To Advance PDS0301 Through Randomized Phase 2B Development Program Over Next 18 To 24 Months

뉴스 본문을 불러오고 있어요.

PDS Biotechnology Announces Strategic Refocus To Prioritize PDS0301 In Metastatic Colorectal Cancer; Expects To Advance PDS0301 Through Randomized Phase 2B Development Program Over Next 18 To 24 Months | 웨이프 WAPE

PDS Biotechnology Announces Strategic Refocus To Prioritize PDS0301 In Metastatic Colorectal Cancer; Expects To Advance PDS0301 Through Randomized Phase 2B Development Program Over Next 18 To 24 Months

기사 요약

관련 종목

댓글 —